A carregar...
Publicação
Catalent´s tumble: from biotech boom to shareholder scrutiny
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 5.03 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
The following paper represents an Equity Research report on
Catalent Inc. The below section is the first part of a two-part series
and focuses on the company itself, and its intrinsic valuation. The
aim of this part is to provide an in-depth analysis of Catalent, its
operations and the current company-specific environment to
facilitate the final intrinsic valuation. The company analysis
includes a segment overview, the acquisition strategy, a SWOT
and Porter’s Five Forces analysis, as well an exploration of current
shareholder allegations. Lastly, a final implied share price is
examined, leading to the recommendation of selling the shares of
Catalent Inc.
Descrição
Palavras-chave
Valuation Healthcare Cdmo Equity research. Catalent